Ignite Creation Date:
2025-12-25 @ 12:01 AM
Ignite Modification Date:
2026-01-10 @ 11:04 PM
Study NCT ID:
NCT01777958
Status:
COMPLETED
Last Update Posted:
2020-12-14
First Post:
2013-01-25
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
HELENA Study: An Observational Study of Perjeta (Pertuzumab) in First-Line Treatment in Patients With Her2-Positive Advanced Breast Cancer After Adjuvant Herceptin Therapy
Sponsor:
Hoffmann-La Roche
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2013-06-14
Start Date Type:
ACTUAL
Primary Completion Date:
2020-11-25
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-11-25
Completion Date Type:
ACTUAL
First Submit Date:
2013-01-25
First Submit QC Date:
None
Study First Post Date:
2013-01-29
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-12-10
Last Update Post Date:
2020-12-14
Last Update Post Date Type:
ACTUAL